| |
Veeva Systems today announced that GSK (gsk.com) will be one of the first top biopharma companies to migrate to Veeva Vault CRM. By adopting the next generation of CRM for life sciences, GSK plans to unlock the new technology innovation to interact with customers based on their needs and in ways that work best for them, leading to more effective healthcare professional (HCP) engagement.
“Data and technology are core to achieving GSK’s aim to positively impact 2.5 billion people by the end of 2030, so moving to Vault CRM is a clear next step for us as we advance our highly tailored HCP engagement,” says Kieron Scrutton, senior vice president of commercial and digital technology at GSK. “Veeva deeply understands the life sciences industry and has the expertise and vision in commercial technology to help biopharma companies like ours bring complex therapies to patients who need them for years to come.”
Scrutton is one of the keynote speakers at Veeva Commercial Summit, Europe. They will share how Vault CRM is a key enabler of future commercial agility, innovation, and differentiation.
GSK field team members rely upon Veeva’s commercial applications to expand and deepen customer relationships and launch new medicines with efficiency and compliance. Vault CRM will include the full functionality of market-leading Veeva CRM on the Veeva Vault Platform, unlocking new opportunities for more connected, customer-centric engagement across sales, medical, and marketing. Vault CRM is part of Veeva Commercial Cloud, the technology foundation for commercial innovation. GSK has adopted Veeva products and services across many other areas of its commercial and development value chains.
“Over the past decade, GSK and Veeva have built a trusted partnership working together to advance its commercial strategy to best support patients,” said Tom Schwenger, president and chief operating officer at Veeva. “GSK will continue its forward-thinking approach to customer relationships by taking full advantage of Vault CRM and future innovations.”
About Veeva Systems
Veeva (veeva.com) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov/.
|
alison.borris[.]veeva.com 
